Dediabetes Logo
Questions
Published answers connected to evidence
Clinical Reference
Detailed intervention and outcome dossiers
Latest Research
Newest studies
About
How deDiabetes works
Settings
Login / Sign-up
Research Summary
Analyzed using Evidence Intelligence™

Liraglutide improves metabolic changes in type 2 diabetes.

Powered by the Dediabetes Evidence Intelligence™ framework

Last updated September 12, 2026

Key finding

Cholesterol esters decreased by approximately 15% from baseline.

This study compared the metabolic effects of liraglutide and glimepiride in type 2 diabetes patients, finding greater reductions in several lipid markers with liraglutide.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

High Risk

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study compared the metabolic effects of liraglutide and glimepiride in type 2 diabetes patients, finding greater reductions in several lipid markers with liraglutide.

Clinical relevance

The findings highlight the potential of liraglutide as a more effective treatment option for managing metabolic abnormalities in type 2 diabetes. Improved lipid profiles can lead to better cardiovascular health and overall diabetes management, making liraglutide a valuable choice for clinicians treating this population.

Keep in mind

The study may have a limited sample size affecting generalizability. Results may not apply to all populations with type 2 diabetes. Long-term effects of treatments were not assessed.

Published in

Journal Reference

Publication details and source links for this paper.

J. J, T. H, M. O, T. N. Liraglutide treatment leads to greater metabolic changes than glimepiride in type 2 diabetes. Cardiovascular Diabetology. 2021;20:237. doi:10.1186/s12933-021-01431-2

View DOIView on PubMedView on PMC

Main Effects

Liraglutide reduced cholesterol esters by approximately 15%.

Significant decreases in hexocyl-ceramides, lysophosphatidylcholines, sphingolipids, and phosphatidylcholines with alkyl ether structure were observed.

Glimepiride showed a lesser reduction in cholesterol esters, approximately 10%.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Glimepiride, Liraglutide and HDL cholesterol, LDL cholesterol, Triglycerides, and 5 more.

This study contributes evidence to

Intervention

Glimepiride

Outcome

HDL cholesterol

Evidence topic

GLP-1 Receptor Agonists

Primary intervention

Glimepiride

Primary outcomes

  • HDL cholesterol
  • LDL cholesterol
  • Triglycerides

Evidence topics

GLP-1 Receptor AgonistsLiraglutideSulfonylureas

Primary intervention

Glimepiride

Primary outcomes

HDL cholesterolLDL cholesterolTriglycerides

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

9
Evidence pairs
9
Relationships
3
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

3

Related topics

9

Evidence pairs

136

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 9 evidence relationships
  • Includes primary outcome data
  • Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

Sulfonylureas and Adipokine and Angiogenic Markers

Related evidence

Evidence topic

GLP-1 Receptor Agonists

Save evidence

Evidence topic

Liraglutide

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

cholesterol esters

Glimepiride → cholesterol esters

Glimepiride → cholesterol esters

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

HDL cholesterol

Glimepiride → HDL cholesterol

Glimepiride → HDL cholesterol

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

LDL cholesterol

Glimepiride → LDL cholesterol

Glimepiride → LDL cholesterol

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Triglycerides

Glimepiride → Triglycerides

Glimepiride → Triglycerides

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

cholesterol esters

Liraglutide → cholesterol esters

Liraglutide → cholesterol esters

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

hexocyl-ceramides

Liraglutide → hexocyl-ceramides

Liraglutide → hexocyl-ceramides

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Lysophosphatidylcholine

Liraglutide → Lysophosphatidylcholine

Liraglutide → Lysophosphatidylcholine

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

phosphatidylcholines with alkyl ether structure

Liraglutide → phosphatidylcholines with alkyl ether structure

Liraglutide → phosphatidylcholines with alkyl ether structure

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Sphingolipids

Liraglutide → Sphingolipids

Liraglutide → Sphingolipids

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

Evidence Suggest

  • Liraglutide treatment led to a 15% decrease in cholesterol esters.
  • Significant reductions in multiple lipid markers were observed with liraglutide.
  • Glimepiride resulted in a smaller 10% decrease in cholesterol esters.
who this applies

Who this applies to

  • Adults diagnosed with type 2 diabetes.
  • Patients requiring pharmacological management for diabetes.
keep in mind

Keep in Mind

  • Results are specific to the studied population and may not generalize.
  • The study did not evaluate long-term outcomes of treatment.
  • Further research is needed to confirm findings across diverse populations.
between the lines

Between the Lines

  • The study may have a limited sample size affecting generalizability.
  • Results may not apply to all populations with type 2 diabetes.
  • Long-term effects of treatments were not assessed.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on Sulfonylureas and cholesterol esters, Sulfonylureas and Adipokine and Angiogenic Markers.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Do Sulfonylureas improve adipokine and angiogenic markers?

Moderate Evidence

Sulfonylureas may improve adipokine and angiogenic markers.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    HDL cholesterol

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

  2. 2

    LDL cholesterol

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

  3. 3

    Triglycerides

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Only a small number of supporting studies are available.
2 supporting studies
View Full Evidence

Does Glimepiride improve cholesterol esters?

Emerging Evidence

Glimepiride appears to improve cholesterol esters.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    cholesterol esters

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence

Does Liraglutide improve lysophosphatidylcholine?

Emerging Evidence

Liraglutide appears to improve lysophosphatidylcholine.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Lysophosphatidylcholine

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence

Does Liraglutide improve sphingolipids?

Emerging Evidence

Liraglutide appears to improve sphingolipids.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Sphingolipids

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

GLP-1 Receptor Agonists Evidence HubLiraglutide Evidence HubSulfonylureas Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Glimepiride and cholesterol estersAll studies on Liraglutide and LysophosphatidylcholineAll studies on Liraglutide and SphingolipidsAll studies on Liraglutide and cholesterol esters

Related research

Read related research summaries.

Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patientsStructured exercise improves metabolic health in prediabetic adultsGLP-1RA improves metabolic outcomes in MASLDLiraglutide 3 mg pathway improves weight loss.

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.